• FDA grants priority review to ripretinib for advanced gastrointestinal stromal tumors

    7 monthes ago - By Healio

    The FDA granted priority review to ripretinib for treatment of advanced gastrointestinal stromal tumors, according to a press release from the agent's manufacturer.
    Ripretinib is a tyrosine kinase switch control inhibitor engineered to broadly inhibit KIT and platelet-derived growth factor receptor alpha-mutated kinases.
    The FDA previously granted fast track and breakthrough therapy designations to the agent for use by patients with previously treated advanced gastrointestinal stromal tumors .
    The agency is expected to make a decision on the new drug
    Read more ...